NASDAQ: GENB
Generate Biomedicines, Inc.CIK 0002100782 · SIC 2834 · Pharmaceutical Preparations
Mid by assets
Assets $562M
as of Oct 4, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
8-K
Filed Aug 26, 2026
· Period ending Aug 25, 2026
Summary not yet generated.
10-Q
Filed Aug 6, 2026
· Period ending Jun 30, 2026
revenue $6.3M, net income -$128.7M. Generate Biomedicines posts H1 2026 loss
5 material changes detected. Sign up free to read the summary.
Partner
Trade GENB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Aug 6, 2026
· Period ending Aug 6, 2026
Summary not yet generated.
10-Q
Filed May 7, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
8-K
Filed May 7, 2026
· Period ending May 7, 2026
Summary not yet generated.
424B4
Filed Feb 27, 2026
Critical
Generate Biomedicines prices $400M IPO at $16/share; net proceeds to fund Phase 3 asthma trials
7 material changes detected. Sign up free to read the summary.
S-1/A
Filed Feb 23, 2026
Summary not yet generated.
S-1/A
Filed Feb 13, 2026
Summary not yet generated.
S-1
Filed Feb 4, 2026
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 6, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share data)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | 6,314 | 10,130 | 13,538 | 18,948 |
| Operating expenses: | ||||
| Research and development(1) | 64,330 | 59,735 | 122,142 | 106,560 |
| General and administrative(2) | 13,598 | 10,545 | 27,122 | 20,692 |
| Total operating expenses | 77,928 | 70,280 | 149,264 | 127,252 |
| Loss from operations | (71,614) | (60,150) | (135,726) | (108,304) |
| Other income (expense), net | ||||
| Change in fair value of convertible preferred stock warrant liability | — | — | (363) | — |
| Interest expense | (155) | (307) | (337) | (675) |
| Interest income | 4,629 | 3,789 | 7,542 | 8,070 |
| Foreign currency exchange loss | (62) | (30) | (4) | (47) |
| Total other income (expense), net | 4,412 | 3,452 | 6,838 | 7,348 |
| Loss before provision for income taxes | (67,202) | (56,698) | (128,888) | (100,956) |
| Provision for income taxes | (53) | (44) | (81) | (100) |
| Net loss | (67,255) | (56,742) | (128,969) | (101,056) |
| Net loss attributable to non-controlling interests | — | (4,313) | (268) | (6,942) |
| Net loss attributable to Generate Biomedicines, Inc. stockholders | (67,255) | (52,429) | (128,701) | (94,114) |
| Convertible preferred stock accrued dividends | — | (11,593) | (7,749) | (23,185) |
| Net loss attributable to Generate Biomedicines, Inc. common stockholders | (67,255) | (64,022) | (136,450) | (117,299) |
| Net loss per share, basic and diluted | (0.52) | (1.94) | (1.41) | (3.57) |
| Weighted average common shares outstanding, basic and diluted | 128,240,371 | 32,996,506 | 96,730,886 | 32,894,770 |
| Other comprehensive loss: | ||||
| Net loss | (67,255) | (56,742) | (128,969) | (101,056) |
| Unrealized loss on marketable securities | (153) | (57) | (235) | (128) |
| Comprehensive loss | (67,408) | (56,799) | (129,204) | (101,184) |
| Comprehensive loss attributable to non-controlling interest | — | (4,313) | (268) | (6,942) |
| Comprehensive loss attributable to Generate Biomedicines, Inc. stockholders | (67,408) | (52,486) | (128,936) | (94,242) |
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share data)
| Description | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 135,359 | 121,650 |
| Marketable securities | 322,056 | 99,848 |
| Restricted cash and cash equivalents (VIE) | — | 339 |
| Prepaid expenses and other current assets | 12,838 | 12,528 |
| Total current assets | 470,253 | 234,365 |
| Property and equipment, net | 27,305 | 29,151 |
| Operating lease right-of-use assets | 55,074 | 59,860 |
| Other assets | 9,058 | 6,806 |
| Total assets | 561,690 | 330,182 |
| Liabilities, convertible preferred stock, non-controlling interest and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable(1) | 5,653 | 3,837 |
| Accrued expenses and other current liabilities | 25,196 | 42,164 |
| Deferred revenue current | 12,168 | 21,194 |
| Current portion of finance lease liabilities | 3,744 | 4,311 |
| Operating lease liabilities current | 9,875 | 10,697 |
| Total current liabilities | 56,636 | 82,203 |
| Non-current liabilities: | ||
| Warrant to purchase convertible preferred stock | — | 1,205 |
| Finance lease liabilities, net of current portion | 1,366 | 2,908 |
| Deferred revenue non-current | — | 4,511 |
| Operating lease liabilities non-current | 47,643 | 50,610 |
| Other long term liabilities | — | 116 |
| Total liabilities | 105,645 | 141,553 |
| Commitments and contingencies (Note 13) | ||
| Convertible preferred stock | — | 811,826 |
| Non-controlling interest | — | (7,232) |
| Stockholders’ equity (deficit): | ||
| Common stock, par value $0.001; 500,000,000 and 200,456,735 shares authorized as of June 30, 2026 and December 31, 2025 respectively; 128,269,428 and 33,116,957 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 128 | 33 |
| Additional paid-in capital | 1,261,040 | 60,189 |
| Accumulated other comprehensive (loss) income | (129) | 106 |
| Accumulated deficit | (804,994) | (676,293) |
| Total stockholders’ equity (deficit) | 456,045 | (615,965) |
| Total liabilities, convertible preferred stock, non-controlling interests and stockholders’ equity (deficit) | 561,690 | 330,182 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | (128,969) | (101,056) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization and accretion on marketable securities | (533) | (1,714) |
| Non-cash stock-based compensation | 14,633 | 10,231 |
| Non-cash lease expense | 4,786 | 2,678 |
| Depreciation and amortization | 6,497 | 6,736 |
| Changes in fair value of convertible preferred stock warrant liability | 363 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | (32) |
| Prepaid expenses and other current assets | (310) | (3,094) |
| Other assets | (2,267) | 3,288 |
| Accounts payable | 1,800 | (151) |
| Operating lease liabilities | (3,789) | (111) |
| Other long term liabilities | (117) | (175) |
| Accrued expenses and other liabilities | (16,888) | 419 |
| Deferred revenue | (13,538) | (18,948) |
| Net cash used in operating activities | (138,332) | (101,929) |
| Investing activities | ||
| Purchase of marketable securities | (321,759) | (142,508) |
| Purchases of property and equipment | (4,714) | (905) |
| Proceeds from sales and maturities of marketable securities | 99,850 | 201,877 |
| Net cash (used in) provided by investing activities | (226,623) | 58,464 |
| Financing activities | ||
| Proceeds from issuance of convertible preferred stock, net of issuance costs | — | 21,972 |
| Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses | 369,289 | — |
| Contributions from non-controlling interests | 7,500 | 2,750 |
| Proceeds from exercise of stock options | 3,631 | 637 |
| Payments on finance lease obligations | (2,108) | (5,062) |
| Net cash provided by financing activities | 378,312 | 20,297 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 13,357 | (23,168) |
| Cash, cash equivalents and restricted cash at beginning of period | 126,036 | 181,831 |
| Cash, cash equivalents and restricted cash at end of period | 139,393 | 158,663 |
| Cash and cash equivalents, end of period | 135,359 | 154,265 |
| Restricted cash and cash equivalents (VIE) | — | 359 |
| Long-term restricted cash | 4,034 | 4,039 |
| Cash, cash equivalents and restricted cash at end of period | 139,393 | 158,663 |
| Supplemental disclosure of noncash investing and financing information: | ||
| Purchase of property and equipment included in the accounts payable and accrued liabilities | 2,002 | 270 |
| Vesting of restricted stock | — | 46 |
| Reclassification of warrant liability to equity upon initial public offering | 1,568 | — |
| Conversion of convertible preferred stock to common stock | 811,826 | — |
Amounts as printed on the EDGAR/iXBRL face — (in thousands, except share and per share data); (in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗